Talphera Inc (TLPH)

$1.15 +0.01 (0.88%)
Market Cap 52.42M
Revenue (ttm) 0.00
Net Income (ttm) -13.00M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 96,800
Avg Vol 3,149,424
Day's Range N/A - N/A
Shares Out 45.59M
Stochastic %K 55%
Beta 0.03
Analysts Strong Sell
Price Target $3.25

Company Profile

Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. The company's lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. It is also developing LTX-608, a nafamostat formulation for direct IV infusion as an investigational product for various indications, such as antiviral,...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 650 216 3500
Address:
1850 Gateway Drive, Suite 175, San Mateo, United States
RyGuy_79
RyGuy_79 Oct. 24 at 3:04 PM
$TLPH
0 · Reply
bobmoney
bobmoney Oct. 24 at 2:46 PM
$TLPH $CRMD CRMD's recent -- strategic investment -- in TLPH up over 100%... CRMD CEO NOW on the Board of TLPH... w/ CEO Joe issued about 40,000 shares of TLPH... TLPH's Phase 3 trials at the Best of the Best of USA medical sites... lead by Primary Investigators that are Nephrologists... !
0 · Reply
bobmoney
bobmoney Oct. 24 at 2:25 PM
$CRMD $TLPH TLPH's top line Phase 3 data on or before December 31, 2025... If TLPH's Niyad is FDA approved... Niyad would be the -- 1st FDA approved anticoagulant for Kidney dialysis in the Extracorporeal Circuit... also likely -- Lungs & Heart... -- HUGE folks & -- count down -- !!
0 · Reply
stevenryl86
stevenryl86 Oct. 24 at 7:44 AM
$TLPH are we in quiet mode? Not much of attention on this
0 · Reply
bobmoney
bobmoney Oct. 23 at 3:35 PM
$CRMD $TLPH Why it matters... TLPH's Niyad Phase 3 data on or before -- December 31, 2025 -- --- Niyad would be the 1st FDA approved... --- !
0 · Reply
RyGuy_79
RyGuy_79 Oct. 23 at 1:52 PM
$TLPH Looks good for liftoff.
0 · Reply
nazzangr
nazzangr Oct. 23 at 2:17 AM
$TLPH i agree! one thing i can say with 100% confidence is that there will be no other drugs like this that has as low risk as nafamostat has when it comes to fda approval. if you are investing in some gene therapy and chemotherapy pharmaceutical and call this a high risk, we got nothing to discuss.
0 · Reply
stevenryl86
stevenryl86 Oct. 22 at 8:25 PM
$TLPH I did My own DD earlier, it will not fail or I can at least failure very low %. https://www.reddit.com/r/pennystocks/s/lSwe6f0736
0 · Reply
CaliEmpress
CaliEmpress Oct. 22 at 8:17 PM
$TLPH Someone somewhere knows something. The rest of us will know about it later this week or next week. I would bet money on it.
1 · Reply
VictoryFormation
VictoryFormation Oct. 22 at 8:06 PM
$TLPH Why is TLPH showing at $0.0 on StockTwits right now?
1 · Reply
Latest News on TLPH
Talphera Announces the Appointment of Joe Todisco to Board of Directors

Oct 21, 2025, 8:30 AM EDT - 4 days ago

Talphera Announces the Appointment of Joe Todisco to Board of Directors

CorMedix Announces Strategic Minority Investment in Talphera

Sep 8, 2025, 8:30 AM EDT - 6 weeks ago

CorMedix Announces Strategic Minority Investment in Talphera

CRMD

Talphera Announces Private Placement Financing of up to $29 Million Priced At-the Market

Sep 8, 2025, 8:30 AM EDT - 6 weeks ago

Talphera Announces Private Placement Financing of up to $29 Million Priced At-the Market

CRMD

Talphera Announces Achievement of 17 Patient Enrollment Milestone in NEPHRO CRRT Pivotal Trial

Aug 25, 2025, 8:30 AM EDT - 2 months ago

Talphera Announces Achievement of 17 Patient Enrollment Milestone in NEPHRO CRRT Pivotal Trial

Talphera, Inc. (TLPH) Q2 2025 Earnings Call Transcript

Aug 14, 2025, 9:10 PM EDT - 2 months ago

Talphera, Inc. (TLPH) Q2 2025 Earnings Call Transcript

Talphera Announces Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 14, 2025, 4:05 PM EDT - 2 months ago

Talphera Announces Second Quarter 2025 Financial Results and Provides Corporate Update

Talphera to Host Second Quarter Financial Results and Corporate Update Call and Webcast on Thursday, August 14, 2025

Aug 7, 2025, 4:35 PM EDT - 2 months ago

Talphera to Host Second Quarter Financial Results and Corporate Update Call and Webcast on Thursday, August 14, 2025

Talphera, Inc. (TLPH) Q1 2025 Earnings Call Transcript

May 14, 2025, 9:01 PM EDT - 5 months ago

Talphera, Inc. (TLPH) Q1 2025 Earnings Call Transcript

Talphera Announces First Quarter 2025 Financial Results and Provides Corporate Update

May 14, 2025, 4:05 PM EDT - 5 months ago

Talphera Announces First Quarter 2025 Financial Results and Provides Corporate Update

Talphera to Host First Quarter Financial Results and Corporate Update Call and Webcast on Wednesday, May 14, 2025

May 7, 2025, 4:05 PM EDT - 6 months ago

Talphera to Host First Quarter Financial Results and Corporate Update Call and Webcast on Wednesday, May 14, 2025

Talphera, Inc. (TLPH) Q4 2024 Earnings Call Transcript

Mar 31, 2025, 6:33 PM EDT - 7 months ago

Talphera, Inc. (TLPH) Q4 2024 Earnings Call Transcript

Talphera Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Mar 31, 2025, 4:05 PM EDT - 7 months ago

Talphera Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Talphera Announces Agreement with the FDA to Reduce the NEPHRO CRRT Study Size to 70 Patients From 166 and a Private Placement Financing Priced At-the Market of up to $14.8 Million

Mar 31, 2025, 8:30 AM EDT - 7 months ago

Talphera Announces Agreement with the FDA to Reduce the NEPHRO CRRT Study Size to 70 Patients From 166 and a Private Placement Financing Priced At-the Market of up to $14.8 Million

Talphera to Host Fourth Quarter and Full-Year 2024 Financial Results and Corporate Update Call and Webcast on Monday, March 31, 2025

Mar 26, 2025, 4:38 PM EDT - 7 months ago

Talphera to Host Fourth Quarter and Full-Year 2024 Financial Results and Corporate Update Call and Webcast on Monday, March 31, 2025

Talphera Announces Agreement with the FDA for Prior Approval Supplement Review to Reduce the Number of Patients in the NEPHRO CRRT Study

Jan 14, 2025, 8:30 AM EST - 10 months ago

Talphera Announces Agreement with the FDA for Prior Approval Supplement Review to Reduce the Number of Patients in the NEPHRO CRRT Study

Talphera, Inc. (TLPH) Q3 2024 Earnings Call Transcript

Nov 13, 2024, 6:43 PM EST - 1 year ago

Talphera, Inc. (TLPH) Q3 2024 Earnings Call Transcript

Talphera Announces Third Quarter 2024 Financial Results and Provides Corporate Update

Nov 13, 2024, 4:05 PM EST - 1 year ago

Talphera Announces Third Quarter 2024 Financial Results and Provides Corporate Update

Talphera to Host Third Quarter 2024 Financial Results and Corporate Update Call and Webcast on Wednesday, November 13, 2024

Nov 6, 2024, 4:05 PM EST - 1 year ago

Talphera to Host Third Quarter 2024 Financial Results and Corporate Update Call and Webcast on Wednesday, November 13, 2024

Talphera to Participate in Fireside Chat at the 2024 Maxim Healthcare Virtual Summit

Oct 8, 2024, 4:54 PM EDT - 1 year ago

Talphera to Participate in Fireside Chat at the 2024 Maxim Healthcare Virtual Summit

Talphera to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

Sep 5, 2024, 4:15 PM EDT - 1 year ago

Talphera to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

Talphera Announces First Patient Enrolled in the Registrational Trial Evaluating Nafamostat for Anticoagulation of the Extracorporeal Circuit

Aug 19, 2024, 8:30 AM EDT - 1 year ago

Talphera Announces First Patient Enrolled in the Registrational Trial Evaluating Nafamostat for Anticoagulation of the Extracorporeal Circuit

Talphera, Inc. (TLPH) Q2 2024 Earnings Call Transcript

Aug 14, 2024, 6:39 PM EDT - 1 year ago

Talphera, Inc. (TLPH) Q2 2024 Earnings Call Transcript

Talphera Announces Second Quarter 2024 Financial Results and Provides Corporate Update

Aug 14, 2024, 4:01 PM EDT - 1 year ago

Talphera Announces Second Quarter 2024 Financial Results and Provides Corporate Update

Talphera to Host Second Quarter 2024 Financial Results and Corporate Update Call and Webcast on Wednesday, August 14, 2024

Aug 5, 2024, 4:05 PM EDT - 1 year ago

Talphera to Host Second Quarter 2024 Financial Results and Corporate Update Call and Webcast on Wednesday, August 14, 2024

Talphera Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

May 20, 2024, 5:25 PM EDT - 1 year ago

Talphera Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Talphera to Participate at A.G.P. Virtual Healthcare Conference

May 16, 2024, 5:45 PM EDT - 1 year ago

Talphera to Participate at A.G.P. Virtual Healthcare Conference

Talphera, Inc. (TLPH) Q1 2024 Earnings Call Transcript

May 14, 2024, 6:21 PM EDT - 1 year ago

Talphera, Inc. (TLPH) Q1 2024 Earnings Call Transcript

Talphera Announces First Quarter 2024 Financial Results and Provides Corporate Update

May 14, 2024, 4:05 PM EDT - 1 year ago

Talphera Announces First Quarter 2024 Financial Results and Provides Corporate Update

Talphera to Host First Quarter 2024 Financial Results Call and Webcast on Tuesday, May 14, 2024

May 2, 2024, 4:15 PM EDT - 1 year ago

Talphera to Host First Quarter 2024 Financial Results Call and Webcast on Tuesday, May 14, 2024

Talphera, Inc. (TLPH) Q4 2023 Earnings Call Transcript

Mar 6, 2024, 9:48 PM EST - 1 year ago

Talphera, Inc. (TLPH) Q4 2023 Earnings Call Transcript

Talphera Announces Fourth Quarter 2023 Financial Results and Provides Corporate Update

Mar 6, 2024, 4:05 PM EST - 1 year ago

Talphera Announces Fourth Quarter 2023 Financial Results and Provides Corporate Update

Talphera Announces Reduction in Size of its Board of Directors from Ten to Seven Members

Mar 1, 2024, 7:30 AM EST - 1 year ago

Talphera Announces Reduction in Size of its Board of Directors from Ten to Seven Members

Talphera to Host Fourth Quarter and Full-Year 2023 Financial Results Call and Webcast on March 6, 2024

Feb 26, 2024, 4:15 PM EST - 1 year ago

Talphera to Host Fourth Quarter and Full-Year 2023 Financial Results Call and Webcast on March 6, 2024

Talphera Announces $26 Million Capital Commitment Through a Combination of a Non-Dilutive Royalty Monetization and Equity Offering

Jan 18, 2024, 8:30 AM EST - 1 year ago

Talphera Announces $26 Million Capital Commitment Through a Combination of a Non-Dilutive Royalty Monetization and Equity Offering

RyGuy_79
RyGuy_79 Oct. 24 at 3:04 PM
$TLPH
0 · Reply
bobmoney
bobmoney Oct. 24 at 2:46 PM
$TLPH $CRMD CRMD's recent -- strategic investment -- in TLPH up over 100%... CRMD CEO NOW on the Board of TLPH... w/ CEO Joe issued about 40,000 shares of TLPH... TLPH's Phase 3 trials at the Best of the Best of USA medical sites... lead by Primary Investigators that are Nephrologists... !
0 · Reply
bobmoney
bobmoney Oct. 24 at 2:25 PM
$CRMD $TLPH TLPH's top line Phase 3 data on or before December 31, 2025... If TLPH's Niyad is FDA approved... Niyad would be the -- 1st FDA approved anticoagulant for Kidney dialysis in the Extracorporeal Circuit... also likely -- Lungs & Heart... -- HUGE folks & -- count down -- !!
0 · Reply
stevenryl86
stevenryl86 Oct. 24 at 7:44 AM
$TLPH are we in quiet mode? Not much of attention on this
0 · Reply
bobmoney
bobmoney Oct. 23 at 3:35 PM
$CRMD $TLPH Why it matters... TLPH's Niyad Phase 3 data on or before -- December 31, 2025 -- --- Niyad would be the 1st FDA approved... --- !
0 · Reply
RyGuy_79
RyGuy_79 Oct. 23 at 1:52 PM
$TLPH Looks good for liftoff.
0 · Reply
nazzangr
nazzangr Oct. 23 at 2:17 AM
$TLPH i agree! one thing i can say with 100% confidence is that there will be no other drugs like this that has as low risk as nafamostat has when it comes to fda approval. if you are investing in some gene therapy and chemotherapy pharmaceutical and call this a high risk, we got nothing to discuss.
0 · Reply
stevenryl86
stevenryl86 Oct. 22 at 8:25 PM
$TLPH I did My own DD earlier, it will not fail or I can at least failure very low %. https://www.reddit.com/r/pennystocks/s/lSwe6f0736
0 · Reply
CaliEmpress
CaliEmpress Oct. 22 at 8:17 PM
$TLPH Someone somewhere knows something. The rest of us will know about it later this week or next week. I would bet money on it.
1 · Reply
VictoryFormation
VictoryFormation Oct. 22 at 8:06 PM
$TLPH Why is TLPH showing at $0.0 on StockTwits right now?
1 · Reply
barlaw
barlaw Oct. 22 at 7:49 PM
$TLPH Kind of a stealth ticker it seems, for some odd reason. Continued low volume days with bullish price action after securing compliance. Could she be fixin’ to run away? Or do we revisit the $1.05 area? Bit of an inverse H&S here, but could be a short term, low volume random thing.
0 · Reply
SGP
SGP Oct. 22 at 6:25 PM
$CRMD if we buy $TLPH shares in the open mkt will crmd have to report that? That would be a good plan to afford the buy out. NO!
2 · Reply
bobmoney
bobmoney Oct. 22 at 5:40 PM
$CRMD $TLPH -- TLPH under accumulation... -- Buying kicked in... CRMD ? !
0 · Reply
barlaw
barlaw Oct. 22 at 5:22 PM
$TLPH Touched $1.08 but with barely 1,000 shares traded. The algos gave them to someone else; skipped my limit order. Ah well. It’s GTC.
0 · Reply
bobmoney
bobmoney Oct. 22 at 5:01 PM
$TLPH always a Buyer too...
0 · Reply
nazzangr
nazzangr Oct. 22 at 4:47 PM
$TLPH sellers market today
0 · Reply
bobmoney
bobmoney Oct. 22 at 3:34 PM
$CRMD $TLPH CRMD CEO brilliant pharma background... CRMD -- brilliant -- strategic investment in TLPH...well explained in video... !
0 · Reply
bobmoney
bobmoney Oct. 22 at 2:10 PM
$CRMD $TLPH TLPH 8K this morning, TLPH -- regained NASDAQ compliance -- TLPH's Niyad pivotal Phase 3 clinical data on or around December 31, 2025... If Niyad FDA approved, -- the 1st FDA approved for indication... -- TLPH's Niyad potential medical treatment Game changer! !
0 · Reply
nazzangr
nazzangr Oct. 22 at 2:07 PM
$TLPH if tlph gets absorbed by crmd. I might keep those shares for the longhaul. So far crmd looks very promising on my dd. I need to do more research though
0 · Reply
bobmoney
bobmoney Oct. 22 at 1:29 PM
$TLPH yep, 8K out this morning... Talphera has regained NASDAQ compliance; congrats
0 · Reply
BioAmerica
BioAmerica Oct. 22 at 12:53 PM
$TLPH Here is the important part of the 8K: "On October 20, 2025, we were notified that we had regained compliance with such minimum price requirement, as the closing bid price of our common stock had been at least $1.00 per share for a minimum of 10 consecutive business days ending October 17, 2025."
0 · Reply
stevenryl86
stevenryl86 Oct. 22 at 12:45 PM
$TLPH compliance done, they released in latest 8K
0 · Reply